Business Context and Reporting Period
This Form 8-K filing by Diamedica Therapeutics Inc. (DMAC) reports on events occurring at the Annual General Meeting (AGM) held on July 15, 2021. The company is incorporated in British Columbia and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders holding 10,748,667 voting common shares (57.2% of outstanding shares) were present at the AGM, constituting a quorum. Two proposals were voted upon:
- Election of Directors: Six nominees were elected to the Board of Directors. New directors Amy Burroughs and Charles Semba, M.D. were elected and will serve on the Audit Committee immediately. Burroughs will also join the Nominating and Corporate Governance Committee, while Dr. Semba will join the Compensation Committee.
- Appointment of Auditors: Shareholders approved the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the year ending December 31, 2021. The proposal received 10,734,645 votes for, 0 votes against, and 14,022 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific committee assignments and independence status of new directors Amy Burroughs and Charles Semba, M.D.
- Confirm the engagement letter terms and scope of work with the newly appointed auditor, Baker Tilly US, LLP.
- Review the definitive proxy statement filed on June 3, 2021, for detailed biographical information on the elected directors.
- Note that 5,721,230 broker non-votes were recorded for the director election, indicating shares held by brokers that were not voted on this matter.